Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity

NCT07804797 | Active Not Recruiting Phase 2

• 1 other identifier: MWN109-Oral-II-MTN
• Study Type: interventional
• Target: 71
• Locations: 1 country
• Sites: 1

Brief Summary

This study adopted a randomized, open-label design, aiming to preliminarily explore the weight-loss maintenance effect of MWN109 tablets when administered continuously for 24 weeks in non-diabetic overweight or obese participants. Participants who met the inclusion criteria were randomly assigned (1:1) to either the QD or QW administration group of MWN109 tablets, with the dose grouping in the MWN109-II-WL study serving as a random stratification factor. This study included a maximum screening period of 2 weeks, a 24-week treatment observation period, and a 2-week safety follow-up period, totaling 28 weeks. The primary endpoint was the percentage change in weight from baseline after 24 weeks of administration. The secondary endpoints included the change in weight from baseline after 24 weeks of administration, as well as the change in waist circumference from baseline.

Conditions

Overweight , Obesity

Outcome Measures

Primary Outcomes (1)

• Percentage change in body weight compared to baseline after 24 weeks of drug administration

  Percentage change in body weight from baseline to Week 24.

  Baseline, Week 24

Secondary Outcomes (8)

• Change from baseline in body weight over time

  Baseline, Week 24

• The proportion of participants whose weight remained unchanged from baseline to week 24

  Baseline, Week 24

• Change from baseline in waist circumference over time

  up to 24 weeks

• Change from baseline in body mass index (BMI) over time

  up to 24 weeks

• Change from baseline in waist-to-hip ratio (WHR) over time

  up to 24 weeks

Study Arms (2)

MWN109 Cohort 1

EXPERIMENTAL

Drug: MWN109 1

MWN109 Cohort 2

EXPERIMENTAL

Drug: MWN109 2

Interventions

MWN109 1 DRUG

Administered orally, QD, 24 weeks

MWN109 Cohort 1

MWN109 2 DRUG

Administered orally, QW, 24 weeks

MWN109 Cohort 2

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participate in the multi-center, randomized, double-blind, placebo-controlled Phase II clinical trial (MWN109-II-WL) to evaluate the efficacy and safety of MWN109 injection in adult non-diabetic overweight or obese participants in China; complete the EOT visit and safety follow-up of the participants.
• Participants whose weight decreased by ≥5% compared to baseline at the EOT visit of the MWN109-II-WL study.
• Participants with a BMI \> 18.5 kg/m² at the time of the safety follow-up in the MWN109-II-WL study and at the time of randomization at Visit 2 (V2) of this study, and who were evaluated by the investigator as suitable for participating in this study.
• Agree not to use other weight-loss drugs or treatments during the study period.
• From the time of signing the informed consent until 3 months after the last dose of the investigational drug, the participant must have no intention of becoming pregnant and must voluntarily use effective contraceptive measures to prevent pregnancy (or ensure their partner does). There must be no plans for sperm or egg donation. Participants of childbearing potential must not be breastfeeding, and the pregnancy test result prior to randomization must be negative.

You may not qualify if:

• Previously diagnosed with type 1, type 2, or any other type of diabetes (excluding gestational diabetes).
• At the EOT visit of the MWN109-II-WL study, the fasting plasma glucose in the central laboratory was ≥ 7.0 mmol/L, or the HbA1c was ≥ 6.5%.
• At the screening stage, the PHQ-9 questionnaire score was ≥ 15; or at the screening stage, there was a suicidal tendency or suicidal behavior, or the subject was judged to have a suicidal risk.
• Plans to participate in another clinical study of a trial drug or device before completing all the scheduled assessments in this clinical study, or to take drugs or non-drug treatments that affect weight (excluding diet and exercise control).

Sponsors & Collaborators

• Shanghai Minwei Biotechnology Co., Ltd: lead

Study Sites (1)

Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China

Location

MeSH Terms

Conditions

Overweight; Obesity

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 31, 2026
• First Posted: September 4, 2026
• Study Start: March 2, 2026
• Primary Completion: September 1, 2026
• Study Completion: September 1, 2026
• Last Updated: September 4, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)